Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - dicloxacillin sodium monohydrate 2.235 g equivalent to to 2 g dicloxicillin. - powder for injection - 2 g - active: dicloxacillin sodium monohydrate 2.235 g equivalent to to 2 g dicloxicillin.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - dicloxacillin sodium monohydrate 27.25 mg/ml equivalent to 39.4 mg/g powder. equiv. to 25 mg/ml dicloxicillin reconst.;   - powder for oral suspension - 25 mg/ml - active: dicloxacillin sodium monohydrate 27.25 mg/ml equivalent to 39.4 mg/g powder. equiv. to 25 mg/ml dicloxicillin reconst.   excipient: orange pineapple 13533081 antibiotic flavour flav- o lok 610049u pineapple flavour aromalok 31194 kaolin microcrystalline cellulose orange flavour saccharin sodium sodium benzoate sodium chloride sodium citrate sucrose

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - dicloxacillin sodium monohydrate 13.625 mg/ml equivalent to 19.7 mg/g of powder. equiv. to 12.5 mg/ml dicloxicillin recon;   - powder for oral suspension - 62.5 mg/5ml - active: dicloxacillin sodium monohydrate 13.625 mg/ml equivalent to 19.7 mg/g of powder. equiv. to 12.5 mg/ml dicloxicillin recon   excipient: orange pineapple 13533081 antibiotic flavour flav-o-lok 610049u pineapple flavour aromaloc 31194 kaolin microcrystalline cellulose orange flavour saccharin sodium sodium benzoate sodium chloride sodium citrate sucrose

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - dicloxacillin sodium monohydrate 275mg equivalent to 250 mg dicloxacillin - capsule - 250 mg - active: dicloxacillin sodium monohydrate 275mg equivalent to 250 mg dicloxacillin excipient: gelatin hydrated silica lactose monohydrate magnesium stearate opacode black s-1-27794

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - dicloxacillin sodium monohydrate 551mg equivalent to 500 mg dicloxacillin - capsule - 500 mg - active: dicloxacillin sodium monohydrate 551mg equivalent to 500 mg dicloxacillin excipient: gelatin hydrated silica lactose monohydrate magnesium stearate opacode black s-1-27794

Australië - Engels - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dicloxacillin sodium, quantity: 542.4 mg (equivalent: dicloxacillin, qty 500 mg) - capsule, hard - excipient ingredients: titanium dioxide; purified water; magnesium stearate; gelatin; colloidal anhydrous silica; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia (note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia).,bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxacillin has less intrinsic antibacterial activity and a narrower spectrum than benzylpenicillin. dicloxacillin should therefore not be used in infections due to organisms susceptible to benzylpenicillin.,important note: when it is judged necessary that treatment is initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates that the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase-resistant penicillin

Australië - Engels - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dicloxacillin sodium, quantity: 271.2 mg (equivalent: dicloxacillin, qty 250 mg) - capsule, hard - excipient ingredients: gelatin; purified water; titanium dioxide; colloidal anhydrous silica; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia (note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia).,bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxacillin has less intrinsic antibacterial activity and a narrower spectrum than benzylpenicillin. dicloxacillin should therefore not be used in infections due to organisms susceptible to benzylpenicillin.,important note: when it is judged necessary that treatment is initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates that the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase-resistant penicillin

Verenigde Staten - Engels - NLM (National Library of Medicine)

a-s medication solutions - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules usp and other antibacterial drugs, dicloxacillin sodium capsules usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility plate testing ). dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal in

Australië - Engels - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dicloxacillin sodium, quantity: 542.4 mg (equivalent: dicloxacillin, qty 500 mg) - capsule, hard - excipient ingredients: titanium dioxide; purified water; magnesium stearate; gelatin; colloidal anhydrous silica; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia (note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia).,bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxacillin has less intrinsic antibacterial activity and a narrower spectrum than benzylpenicillin. dicloxacillin should therefore not be used in infections due to organisms susceptible to benzylpenicillin.,important note: when it is judged necessary that treatment is initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates that the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase-resistant penicillin

Australië - Engels - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dicloxacillin sodium, quantity: 271.2 mg (equivalent: dicloxacillin, qty 250 mg) - capsule, hard - excipient ingredients: gelatin; purified water; titanium dioxide; colloidal anhydrous silica; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia (note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia).,bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxacillin has less intrinsic antibacterial activity and a narrower spectrum than benzylpenicillin. dicloxacillin should therefore not be used in infections due to organisms susceptible to benzylpenicillin.,important note: when it is judged necessary that treatment is initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates that the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase-resistant penicillin